chronic hepatitis c, genotype 1

hcv rna ≥100,000 iu/ml at screening

liver biopsy documenting no cirrhosis (within prior 3 years). where approved for staging of liver disease, non-invasive imaging may be used to assess the extent of liver disease

naïve to prior anti-hcv therapy

infected with hcv other than genotype 1

positive hepatitis b surface antigen (hbsag), or human immunodeficiency virus (hiv)-1/hiv-2 antibody at screening

evidence of liver disease other than hcv

active substance abuse

use of hematologic growth factors within 90 days prior to study randomization

evidence of history of cirrhosis based on radiologic criteria or biopsy results and clinical criteria